



December 20, 2021

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi

Dear Sir,

Sub: Disclosure of Price Sensitive Information – Due Diligence of M/s Sanofi Aventis Pakistan Limited

Today, Packages Limited made a public announcement that its Board of Directors gave an in-principle approval to be part of an investor consortium (the “**Consortium**”) to evaluate a potential purchase by the Consortium of all of 52.87% shares held by Sanofi Foreign Participations B.V. (“**Sanofi**”) in sanofi-aventis Pakistan Limited (the “**Company**”), subject to compliance with all applicable laws. The Consortium would comprise Packages Limited, IGI Investments (Private Limited), and affiliates of Arshad Ali Gohar Group. Please note that IGI Holdings Limited has also made a similar announcement on behalf of its 100% wholly owned subsidiary IGI Investments (Private) Limited (a member of the Consortium).

The management of Sanofi has informed the Company that Sanofi will be giving the Consortium an opportunity to conduct due diligence of the Company and commence negotiations on terms and conditions of the potential transaction.

The Company will perform its role in accordance with the applicable laws in the proposed transaction process, including, but not limited to, the due diligence process, conducting management presentations, organizing site visits, and finalisation of transaction related agreements (if relevant).

“We do not expect any disruption to the manufacturing, marketing, distribution, or availability of Sanofi products in Pakistan. Healthcare providers, patients and caregivers are assured of the continuity of supply of Sanofi products in the immediate future as well as in the long term” said Dr Asim Jamal (Managing Director of sanofi-aventis Pakistan Limited).

There are no assurances that the negotiations between Sanofi and the Consortium will result in any binding agreement and that the transaction will occur at all.

A disclosure form as required under S.R.O. 143/(1)/2012 dated December 05, 2012 read with Sections 96 and 131 of the Securities Act, 2015 is also enclosed as an Annexure hereto.

8

sanofi-aventis Pakistan limited

Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900, Pakistan
PABX: +92-21-35060221-35 Fax: +92-21-35060358 Web: sanofi.com.pk



You are requested to disseminate the information to the Members of the Exchange accordingly.

Yours faithfully,

For and on behalf of

sanofi-aventis Pakistan Limited

Muhammad Abu Bakar Siddiq

Company Secretary

Encl: As Above

Cc: (i) Director/HOD-Surveillance, Supervision and Enforcement Department, Securities and Exchange Commission of Pakistan, NIC Building, 63 Jinnah Avenue Blue Area, Islamabad; and

(ii) Company Registration Office, Securities & Exchange Commission of Pakistan, 4th Floor, State Life Building No. 2, Wallace Road, Karachi

sanofi-aventis Pakistan limited

Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900, Pakistan
PABX: +92-21-35060221-35 Fax: +92-21-35060358 Web: sanofi.com.pk



ANNEXURE

DISCLOSURE FORM
INTERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015

Name of Company	sanofi-aventis Pakistan Limited
Date of Report	December 20, 2021
Name of Company as specified in The Memorandum	sanofi-aventis Pakistan Limited
Company's Registered Office	Plot No. 23, Sector-22, Korangi Industrial Area, Karachi
Contact Information	Tel: +92 21 35060221-35

Disclosure of price sensitive / inside information by listed company in terms of Section 96 and 131:

Today, Packages Limited made a public announcement that its Board of Directors gave an in-principle approval to be part of an investor consortium (the "**Consortium**") to evaluate a potential purchase by the Consortium of all of 52.87% shares held by Sanofi Foreign Participations B.V. ("**Sanofi**") in sanofi-aventis Pakistan Limited (the "**Company**"), subject to compliance with all applicable laws. The Consortium would comprise Packages Limited, IGI Investments (Private Limited), and affiliates of Arshad Ali Gohar Group. Please note that IGI Holdings Limited has also made a similar announcement on behalf of its 100% wholly owned subsidiary IGI Investments (Private) Limited (a member of the Consortium).

The management of Sanofi has informed the Company that Sanofi will be giving the Consortium an opportunity to conduct due diligence of the Company and commence negotiations on terms and conditions of the potential transaction.

The Company will perform its role in accordance with the applicable laws in the proposed transaction process, including, but not limited to, the due diligence process, conducting management presentations, organizing site visits, and finalisation of transaction related agreements (if relevant).

"We do not expect any disruption to the manufacturing, marketing, distribution, or availability of Sanofi products in Pakistan. Healthcare providers, patients and caregivers are assured of the continuity of supply of Sanofi products in the immediate future as well as in the long term" said Dr Asim Jamal (Managing Director of sanofi-aventis Pakistan Limited).

There are no assurances that the negotiations between Sanofi and the Consortium will result in any binding agreement and that the transaction will occur at all.

Intimation of decision of the listed company to delay disclosure of inside information in terms of Section 96(4).

NIL

Disclosure of inside information by listed company where the listed company or person acting on its behalf discloses inside information to third party in terms of Section 131.

NIL



sanofi-aventis Pakistan limited

Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900, Pakistan
PABX: +92-21-35060221-35 Fax: +92-21-35060358 Web: sanofi.com.pk



- Disclosure of transactions conducted by persons discharging managerial responsibilities within a listed company or persons closely associated with them.

NIL

For and on behalf of

sanofi-aventis Pakistan Limited

Muhammad Abu Bakar Siddiq

Company Secretary

sanofi-aventis Pakistan limited

Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900, Pakistan
PABX: +92-21-35060221-35 Fax: +92-21-35060358 Web: sanofi.com.pk